12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afrezza: Phase III data

Preliminary data from the double-blind, placebo-controlled, international Phase III AFFINITY 2 trial (Study 175) in 353 Type II diabetics showed that Afrezza administered via MannKind's next-generation Dreamboat inhaler added to patients' oral therapy met the primary endpoint of superiority to placebo plus oral therapy in reducing mean HbA1c levels from baseline to 24 weeks (0.82% vs. 0.42%, p<0.0001). Furthermore, a greater proportion of patients in the Afrezza arm achieved HbA1c target levels of <7% (37.7% vs. 19%, p=0.0005) and <6.5% (15.9% vs. 4.2%,...

Read the full 395 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >